quinidine gluconate profile

Quinidine gluconate is a salt of quinidine, an antiarrhythmic drug used to treat certain types of irregular heartbeats. It is synthesized by reacting quinidine with gluconic acid. Quinidine gluconate works by blocking sodium channels and potassium channels in the heart, which helps to regulate the heart's rhythm. It can cause side effects such as nausea, vomiting, diarrhea, and dizziness. Quinidine gluconate is studied because of its potential to treat atrial fibrillation, a type of irregular heartbeat. It is also used to treat other heart rhythm disorders.'

quinidine gluconate: RN given refers to (9S)-isomer & ratio of [1:1] [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	94328
CHEMBL ID	1200437
CHEBI ID	27502
SCHEMBL ID	41479
SCHEMBL ID	15541190
MeSH ID	M0066906

Synonym
KBIO1_000228
DIVK1C_000228
SPECTRUM5_001080
IDI1_000228
SPECTRUM_000910
quinalan
duraquin
cinchonan-9-ol, 6'-methoxy-, (9s)-, mono-d-gluconate (salt)
einecs 230-333-9
quinidine, d-gluconate (salt)
quinidine mono-d-gluconate (salt)
quinatime
quinidine gluconate
CHEBI:27502 ,
(9s)-6'-methoxycinchonan-9-ol--d-gluconic acid (1:1)
quinidine d-gluconate
quinidine gluconate (usp)
KBIOGR_001393
KBIO3_001806
KBIO2_003958
KBIO2_006526
KBIOSS_001390
KBIO2_001390
NINDS_000228
SPECTRUM2_000408
SPBIO_000336
SPECTRUM3_000893
SPECTRUM4_000987
SPECTRUM1500523
HMS2092E19
gluconic acid quinidine salt
dura-tab
quinidine monogluconate, d-
quinidine mono-d-gluconate
gluquinate
CHEMBL1200437
nsc-757297
HMS500L10
HMS1920N18
pharmakon1600-01500523
nsc757297
einecs 229-517-1
6587-33-3
d-gluconic acid, compound with (9s)-6'-methoxycinchonan-9-ol
CCG-38674
r6875n380f ,
quinidine gluconate [usp]
unii-r6875n380f
nsc 757297
cinchonan-9-ol, 6'-methoxy-, (9s)-, mono-d-gluconate
quinidine gluconate [orange book]
quinidine gluconate [usp monograph]
quinidine gluconate [mi]
quinidine gluconate [vandf]
quinidine gluconate [usp-rs]
quinidine gluconate [who-dd]
quinidine gluconate [mart.]
SCHEMBL41479
SCHEMBL15541190
W-110193
quinidine gluconate, united states pharmacopeia (usp) reference standard
SR-05000001710-2
sr-05000001710
SR-05000001710-1
quinidine gluconate salt, analytical standard
Q27094388
(s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid
EX-6000
DTXSID801027497
HY-B1751F
CS-0030857
9s-6'-methoxy-cinchonan-9-ol, mono-d-gluconate(salt)
quinidine gluonate
quinidine gluconate (usp-rs)
quinidine gluconate (mart.)
quinidine gluconate (usp monograph)

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" The elimination half-life was 12."	( Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. Karbwang, J; Looareesuwan, S; Phillips, RE; Warrell, DA; White, NJ, 1985)	0.27
" Further application of the BSP for pharmacodynamic monitoring will require electrode refinements and an increased understanding of its mechanism of action."	( The pharmacodynamic response of the basal skin potential to quinidine gluconate. Ando, HY; Escobar, A; Schnaare, RL; Sugita, ET, 1986)	0.51

Bioavailability

Steady-state bioavailability of sustained-release quinidine gluconate tablets manufactured by two companies was compared in a crossover study.

Excerpt	Reference	Relevance
"The effect of aluminum hydroxide gel on quinidine gluconate bioavailability was studied in eight nonsmoking healthy male volunteers."	( Effect of aluminum hydroxide gel on quinidine gluconate absorption. Fraker, TD; Mauro, LS; Mauro, VF; Somani, P; Temesy-Armos, PN, 1990)	0.82
" Under the conditions of the study, both the rate and extent of quinidine bioavailability was significantly affected by food."	( Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet. Brown, WJ; Gallo, JM; Hemingway, SM; Honigberg, IL; Kotzan, JA; Martinez, MN; Pelsor, FR; Shah, VP; Skelly, JP; Zaman, R, )	0.36
"Simulated data using a linear one- and two-compartment body model with different absorption characteristics were used to evaluate the ability of single dose bioavailability data to predict the relationships that exist at steady state."	( Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics. Jackson, AJ, )	0.13
"Steady-state bioavailability of sustained-release quinidine gluconate tablets manufactured by two companies was compared in a crossover study."	( Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state. Taggart, WV; Zinny, MA, 1984)	0.77
"Steady-state bioavailability of a sustained-release quinidine gluconate formulation was compared with that of a sustained-release quinidine sulfate preparation in a crossover study."	( Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Holyoak, W; Taggart, WV, 1983)	0.74
"A recently marketed prolonged-release quinidine gluconate tablet was compared with the innovator's tablet in a single-dose bioavailability study with 12 healthy male subjects."	( Serious bioavailability problems with a generic prolonged-release quinidine gluconate product. Jacob, J; Lieberman, P; Meyer, MC; Straughn, AB, )	0.64
" oral bioavailability of quinidine was, unexpectedly, greater than 100% (147 +/- 44%)."	( Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Darbar, D; Dell'Orto, S; Roden, DM; Wilkinson, GR, 1996)	0.73

Dosage Studied

Two different chronic dosing regimens of quinidine gluconate were administered to each of four healthy volunteers in a pilot study. In a cross-over study, 2 commercial dosage forms of the same drug were given to 18 healthy subjects who fasted for 10 hours.

Excerpt	Relevance	Reference
" As a consequence of Tmax and Cmax decreasing and increasing from single to multiple dosing regimens, the confidence intervals for these parameters reflected these changes."	( Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics. Jackson, AJ, )	0.13
" Patient population estimates were then derived to predict the quinidine dosage necessary to achieve given plasma concentrations."	( Quinidine dosage in children using population estimates. Burckart, GJ; Marin-Garcia, J, 1986)	0.27
" The proposed procedure was applied to currently marketed samples of quinidine salts and their dosage forms."	( Analysis of Cinchona alkaloids by high-performance liquid chromatography. Application to the analysis of quinidine gluconate and quinidine sulfate and their dosage forms. Smith, E, 1984)	0.48
" Medication dosages, dosing intervals, and time elapsed from last dosage until blood sampling were determined."	( Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance. Fuster, V; Goldman, ME; Kupersmith, J; Schweitzer, P; Squire, A; Stern, EH, 1984)	0.27
" The tablets manufactured by Berlex provided statistically significantly higher plasma levels during the second half of the dosing interval (six to 12 hours postdose)."	( Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state. Taggart, WV; Zinny, MA, 1984)	0.51
" In a cross-over study, 2 commercial dosage forms of quinidine gluconate, fast- and slow-release, were administered to 18 healthy subjects who had fasted for 10 hours in 3 treatments which were administered during the fasting period (T1), and before (T2) of after (T3) a standard breakfast."	( Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state. Gagnon, MA; Sirois, G; St-Onge, JM, )	0.59
"Two different chronic dosing regimens of quinidine gluconate were administered to each of four healthy volunteers in a pilot study to evaluate quinidine for nonlinear pharmacokinetics."	( Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing. Pershing, LK; Russo, J; Russo, ME; Smith, RA, )	0.76
"Blood quinidine levels obtained by single and multiple dosage schedules of all available quinidine preparations were ascertained."	( THE RELATIONSHIP OF DOSAGE SCHEDULE TO THE BLOOD LEVEL OF QUINIDINE, USING ALL AVAILABLE QUINIDINE PREPARATIONS. CHAKRABARTI, SG; GOLDBERG, WM, 1964)	0.24

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Class	Description
D-gluconate adduct
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (50.00)	18.7374
1990's	15 (25.86)	18.2507
2000's	6 (10.34)	29.6817
2010's	8 (13.79)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	8 (12.31%)	5.53%
Reviews	2 (3.08%)	6.00%
Case Studies	20 (30.77%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (53.85%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Impact of Nuedexta on Bulbar Physiology and Function in ALS [NCT03883581]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2019-07-25	Completed
A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorp [NCT02171546]	Phase 1	42 participants (Actual)	Interventional	2007-11-30	Terminated
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With A [NCT00573443]	Phase 3	326 participants (Actual)	Interventional	2007-12-31	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Dep [NCT02153502]	Phase 2	206 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, 2-Part, Crossover, Single Center Study to Evaluate Effect of Quinidine on the Pharmacokinetics of NKTR-118 and the Concomitant Effect of Quinidine and NKTR-118 on Morphine-induced Miosis [NCT01533155]	Phase 1	214 participants (Actual)	Interventional	2012-03-31	Completed
A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects [NCT01460381]	Phase 1	18 participants (Actual)	Interventional	2011-10-31	Completed
A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects [NCT01873950]	Phase 1	22 participants (Actual)	Interventional	2013-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00573443 (7) [back to overview]	Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score
NCT00573443 (7) [back to overview]	Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects
NCT00573443 (7) [back to overview]	PBA Episode Rate Ratio (Post/Pre), Regression Adjusted
NCT00573443 (7) [back to overview]	Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category
NCT00573443 (7) [back to overview]	Mean Change From Baseline in CNS-LS Total Score by Visit
NCT00573443 (7) [back to overview]	Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)
NCT00573443 (7) [back to overview]	Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)
NCT01460381 (6) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [(AUC(0-∞)] of LY2216684 + Quinidine in Cytochrome P450 (CYP)2C19 Poor Metabolizers (PM)
NCT01460381 (6) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)
NCT01460381 (6) [back to overview]	Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers
NCT01460381 (6) [back to overview]	Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)
NCT01460381 (6) [back to overview]	Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers
NCT01460381 (6) [back to overview]	Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)
NCT01873950 (10) [back to overview]	Change in Relationship (Ratio) Between Heart Rate and QT
NCT01873950 (10) [back to overview]	Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]	Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]	Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]	Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]	Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle
NCT01873950 (10) [back to overview]	Placebo, and Baseline-adjusted Changes in Ventricular Gradient
NCT01873950 (10) [back to overview]	Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]	Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]	Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc
NCT03883581 (5) [back to overview]	Bamboo Passage Reading Duration (in Seconds)
NCT03883581 (5) [back to overview]	Change in ALSFRS-R Bulbar Subscale Score
NCT03883581 (5) [back to overview]	Change in Dynamic Imaging Grade of Swallowing Toxicity
NCT03883581 (5) [back to overview]	Change in Patient-reported Outcome: Center for Neurologic Study-Bulbar Function Scale (CNS-BFS)
NCT03883581 (5) [back to overview]	Change in Speech Intelligibility

Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score

The BDI-II is a 21-item self report instrument intended to assess the existence and severity of symptoms of depression, summed to give a single score. The BDI-II uses a 4-point for each item ranging from 0 to 3. A total score of 0-13 is considered minimal range, 14 to 19 is mild, 20 to 28 is moderate, and 29 to 63 is severe. (NCT00573443)
Timeframe: Baseline and Day 84

Intervention	Scores on a Scale (Mean)
AVP-923-30	-1.59
AVP-923-20	-1.03
Placebo	-0.02

Intervention	Scores on a Scale (Mean)
	Physical Functioning Scale	Role Physical Scale	Bodily Pain Scale	General Health Scale	Vitality Scale	Social Functioning Scale	Role Emotional Scale	Mental Health Scale
AVP-923-20	-5.30	-4.26	5.84	-2.95	-5.30	1.42	-1.81	3.09
AVP-923-30	-0.90	3.47	4.09	-1.47	-0.90	9.34	11.55	5.53
Placebo	-4.05	-1.75	-1.13	-1.28	-4.05	-3.09	2.36	-0.28

Intervention	Scores on a Scale (Mean)
	Day 15 (Visit2)	Day 29 (Visit 3)	Day 57 (Visit 4)	Day 84 (Visit 5)
AVP-923-20	-6.27	-7.62	-8.89	-8.24
AVP-923-30	-6.77	-8.03	-8.59	-8.17
Placebo	-4.58	-5.70	-5.66	-5.72

Intervention	Scores on a Scale (Mean)
	Frequency Score	Severity Score
AVP-923-20	-3.09	-1.81
AVP-923-30	-1.68	-0.80
Placebo	-1.25	-0.91

Intervention	nanogramshours per milliliter (ngh/mL) (Geometric Mean)
LY2216684 (CYP2C19 Poor Metabolizers)	749
LY2216684 (CYP2C19 Extensive Metabolizers)	698

Intervention	nanograms per milliliter (ng/mL) (Geometric Mean)
LY2216684 (CYP2C19 Poor Metabolizers)	54.7
LY2216684 (CYP2C19 Extensive Metabolizers)	54.8

Intervention	hours (Median)
LY2216684 (CYP2C19 Poor Metabolizers)	2.00
LY2216684 (CYP2C19 Extensive Metabolizers)	2.00

Intervention	ratio (Mean)
Ranolazine 1500mg	0.01
Dofetilide 500mcg	0.06
Verapamil HCl 120 mg	0.02
Quinidine Sulfate 400mg	0.11

Intervention	degrees (Least Squares Mean)
Ranolazine 1500mg	-2.2
Dofetilide 500mcg	-4.9
Verapamil HCl 120 mg	-2.4
Quinidine Sulfate 400mg	3.9

Intervention	ms per ng/ml (Mean)
	Change in PR	Change in QTc	Change in QRS	Change in J-Tpeakc	Change in Tpeak-Tend
Dofetilide 500mcg	-0.5	73.6	0.2	39.1	34.4
Verapamil HCl 120 mg	28.7	3.9	0.3	-0.7	3.6

Intervention	ms (Least Squares Mean)
	Change in PR interval	Change in QRS duration	Change in J-Tpeakc	Change in Tpeak-Tend	Change in QTc
Dofetilide 500mcg	2.3	1.1	39.5	40.0	79.3
Quinidine Sulfate 400mg	5.1	2.1	29.1	49.8	78.1
Ranolazine 1500mg	6.5	2.7	3.3	8.8	12.6
Verapamil HCl 120 mg	32.1	2.6	-2.4	4.8	5.2

Intervention	Seconds (Mean)
	Pre Nuedexta	Post Nuedexta
ALS Individuals With Bulbar Dysfunction	66.19	65.33

Intervention	score on a scale (Mean)
	Pre Nuedexta	Post Nuedextaa
ALS Individuals With Bulbar Dysfunction	7.47	8.39

Intervention	Participants (Count of Participants)
	Pre Nuedexta DIGEST 0 (Normal)	Post Nuedexta DIGEST 0 (Normal)
ALS Individuals With Bulbar Dysfunction	3	7

Substance	Relationship Strength	Studies	Trials	Classes	Roles
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	1.99	1	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	1.96	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	1.97	1	0	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	1.96	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
halothane [no description available]	1.98	1	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.08	1	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	1.96	1	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.37	2	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	1.97	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	1.96	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	1.97	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	1.96	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	4.33	6	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	1.97	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	1.97	1	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.17	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	3.75	2	1	organic molecular entity
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	1.96	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
lorcainide [no description available]	8.35	1	1	acetamides
sulfadiazine, trimethoprim drug combination sulfadiazine, trimethoprim drug combination: combination of trimethoprim & sulfadiazine	1.97	1	0
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.09	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
artesunic acid [no description available]	3.55	2	0
hydroquinidine hydroquinidine: urinary quinine metabolite; RN given refers to (9S)-isomer; structure in Merck Index, 9th ed, #4703	1.94	1	0	cinchona alkaloid
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	10.78	55	6	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
pectins Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.	1.94	1	0	D-galactopyranuronic acid
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.55	2	0
sesquiterpenes [no description available]	3.09	1	0
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.65	3	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
quinine [no description available]	9.04	4	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
3-hydroxyquinidine 3-hydroxyquinidine: RN given refers to (9S)-isomer	6.97	1	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	1.96	1	0
piperidines Piperidines: A family of hexahydropyridines.	3.35	1	1

Condition	Indicated	Relationship Strength	Studies	Trials
Encephalitis, Polio [description not available]	0	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	0	2.06	1	0
Plasmodium falciparum Malaria [description not available]	0	9.46	8	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	4.46	8	0
Babesia Infection [description not available]	0	2.15	1	0
Retinal Pigment Epithelial Detachment [description not available]	0	2.17	1	0
Hemorrhage, Retinal [description not available]	0	2.17	1	0
Cerebral Malaria [description not available]	0	3.36	2	0
Travel Sickness [description not available]	0	2.17	1	0
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	0	2.17	1	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	0	2.08	1	0
Acute Kidney Failure [description not available]	0	2.08	1	0
Bilirubinemia [description not available]	0	2.08	1	0
Thrombopenia [description not available]	0	2.08	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	2.08	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	2.08	1	0
Arrhythmia [description not available]	0	5.41	8	2
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	1	7.41	8	2
Auricular Fibrillation [description not available]	0	3.98	5	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	3.98	5	0
Gastric Ulcer [description not available]	0	2.02	1	0
Gastritis, Atrophic GASTRITIS with atrophy of the GASTRIC MUCOSA, the GASTRIC PARIETAL CELLS, and the mucosal glands leading to ACHLORHYDRIA. Atrophic gastritis usually progresses from chronic gastritis.	0	2.02	1	0
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	0	2.02	1	0
Breathlessness [description not available]	0	2.03	1	0
Fever of Unknown Origin Fever in which the etiology cannot be ascertained.	0	2.03	1	0
Icterus [description not available]	0	2.03	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	2.03	1	0
Dyspnea Difficult or labored breathing.	0	2.03	1	0
Jaundice A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.	0	2.03	1	0
Elliptocytosis, Hereditary An intrinsic defect of erythrocytes inherited as an autosomal dominant trait. The erythrocytes assume an oval or elliptical shape.	0	2.04	1	0
Acute Hemolytic Transfusion Reaction [description not available]	0	2.04	1	0
Transfusion Reaction Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.	0	2.04	1	0
Cardiac Diseases [description not available]	0	1.96	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	1.96	1	0
Anemia, Hypoplastic [description not available]	0	2.37	2	0
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	0	2.37	2	0
Canine Diseases [description not available]	0	2.37	2	0
Flatus [description not available]	0	1.96	1	0
Gastric Volvulus [description not available]	0	1.96	1	0
Flatulence Production or presence of gas in the gastrointestinal tract which may be expelled through the anus.	0	1.96	1	0
Bovine Diseases [description not available]	0	1.96	1	0
Anomalous Ventricular Excitation Syndrome [description not available]	0	1.96	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	0	1.96	1	0
Wolff-Parkinson-White Syndrome A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.	0	1.96	1	0
Libman-Sacks Disease [description not available]	0	2.9	1	0
Forestier-Certonciny Syndrome [description not available]	0	2.9	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.9	1	0
Polymyalgia Rheumatica A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.	0	2.9	1	0
Infections, Plasmodium [description not available]	0	4.76	12	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	1	6.76	12	0
A-V Dissociation [description not available]	0	1.99	1	0
Cardiac Arrest, Sudden [description not available]	0	1.99	1	0
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	0	1.99	1	0
Atrioventricular Nodal Re-Entrant Tachycardia [description not available]	0	2.39	2	0
Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).	0	2.39	2	0
Cardiac Complex, Premature [description not available]	0	3.34	1	1
Equine Diseases [description not available]	0	1.98	1	0
Complication, Postoperative [description not available]	0	1.98	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	1.98	1	0
Emergencies Situations or conditions requiring immediate intervention to avoid serious adverse results.	0	1.97	1	0
Torsade de Pointes [description not available]	0	1.97	1	0
Tachyarrhythmia [description not available]	0	2.66	3	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	0	7.66	3	0
Candida Infection [description not available]	0	1.96	1	0
Dysphagia [description not available]	0	1.96	1	0
Cancer of Esophagus [description not available]	0	1.96	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	0	1.96	1	0
Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.	0	1.96	1	0
Esophageal Diseases Pathological processes in the ESOPHAGUS.	0	1.96	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	1.96	1	0
Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.	0	1.96	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	1.96	1	0

quinidine gluconate

Description

Cross-References

Synonyms (76)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Bioassays (4)

Research

Studies (58)

Market Indicators

Research Demand Index: 37.40

Study Types

Clinical Trials (7)

Trial Overview

Trial Outcomes

Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score

Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects

PBA Episode Rate Ratio (Post/Pre), Regression Adjusted

Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category

Mean Change From Baseline in CNS-LS Total Score by Visit

Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)

Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)

Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [(AUC(0-∞)] of LY2216684 + Quinidine in Cytochrome P450 (CYP)2C19 Poor Metabolizers (PM)

Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)

Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers

Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)

Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers

Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)

Change in Relationship (Ratio) Between Heart Rate and QT

Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)

Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)

Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)

Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)

Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle

Placebo, and Baseline-adjusted Changes in Ventricular Gradient

Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)

Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)

Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc

Bamboo Passage Reading Duration (in Seconds)

Change in ALSFRS-R Bulbar Subscale Score

Change in Dynamic Imaging Grade of Swallowing Toxicity

Change in Patient-reported Outcome: Center for Neurologic Study-Bulbar Function Scale (CNS-BFS)

Change in Speech Intelligibility

Related Drugs (32)

Related Conditions (72)